ONO-8809 is a thromboxane A2 receptor antagonist potentially for the treatment of stroke. ONO-8809 inhibited the LTC4-induced airway hyperresponsiveness to histamine in a dose-dependent manner, but not the airway wall thickening induced by LTC4, suggesting that the effect of LTC4 on bronchial hyperresponsiveness is likely to be mediated through TXA2. Macrophage accumulation and matrix metalloproteinase-9 (MMP-9) activity in the stroke-negative area in the contralateral cerebral cortex to the stroke lesion of salt-loaded SHRSP and 8-iso-PGF2alpha-treated SHRSP were significantly reduced by ONO-8809 treatment. References: Ishizuka T, Niwa A, Tabuchi M, Nagatani Y, Ooshima K, Higashino H. Involvement of thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone rats. J Hypertens. 2007 Apr;25(4):861-70. PubMed PMID: 17351380.

纯度：≥98%

CAS：123288-47-1